autophagy-lysosome-dysfunction

Autophagy-Lysosome Dysfunction in Neurodegeneration

Introduction

The autophagy-lysosome pathway (ALP) is the principal degradative system for long-lived , protein aggregates, and damaged organelles in [neurons](/entities/neurons). Because neurons are post-mitotic and cannot dilute toxic material through cell division, they depend critically on efficient autophagy for survival[@human]. Dysfunction of this pathway is now recognized as a convergent pathological feature across virtually all major neurodegenerative , including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and frontotemporal dementia[@role]. PMID: 34130600

This page details the molecular machinery of autophagy, the specific points of failure in neurodegeneration, disease-specific disruptions, and emerging therapeutic strategies targeting the ALP.

Overview of the Autophagy-Lysosome Pathway

The autophagy-lysosome pathway operates through three principal routes: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). Each converges on lysosomes — acidic organelles containing over 60 hydrolases that degrade macromolecular cargo to recyclable building blocks. In neurons, autophagosomes form primarily in distal axons and must undergo retrograde transport over distances exceeding one meter in motor neurons before fusing with perinuclear lysosomes[@brainderived].

Autophagy-Lysosome Dysfunction in Neurodegeneration

Introduction

The autophagy-lysosome pathway (ALP) is the principal degradative system for long-lived , protein aggregates, and damaged organelles in [neurons](/entities/neurons). Because neurons are post-mitotic and cannot dilute toxic material through cell division, they depend critically on efficient autophagy for survival[@human]. Dysfunction of this pathway is now recognized as a convergent pathological feature across virtually all major neurodegenerative , including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and frontotemporal dementia[@role]. PMID: 34130600

This page details the molecular machinery of autophagy, the specific points of failure in neurodegeneration, disease-specific disruptions, and emerging therapeutic strategies targeting the ALP.

Overview of the Autophagy-Lysosome Pathway

The autophagy-lysosome pathway operates through three principal routes: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). Each converges on lysosomes — acidic organelles containing over 60 hydrolases that degrade macromolecular cargo to recyclable building blocks. In neurons, autophagosomes form primarily in distal axons and must undergo retrograde transport over distances exceeding one meter in motor neurons before fusing with perinuclear lysosomes[@brainderived].

Types of Autophagy

Macroautophagy

Macroautophagy (hereafter "autophagy") is the best-characterized pathway and the most relevant to neurodegeneration. It involves the de novo formation of double-membraned autophagosomes that engulf cytoplasmic cargo and deliver it to lysosomes.

Initiation: Under nutrient-replete conditions, mTORC1 phosphorylates and inhibits the ULK1 complex. Starvation, energy stress (via AMPK), or specific signals relieve this inhibition, activating ULK1, which phosphorylates Beclin-1 and VPS34 to initiate phagophore nucleation[@association].

Elongation and closure: Two ubiquitin-like conjugation systems — ATG12-ATG5-ATG16L1 and LC3-phosphatidylethanolamine (LC3-II) — drive membrane expansion. LC3-II decorates both inner and outer autophagosomal membranes and serves as the canonical autophagy marker[@mitochondrial]. PMID: 33812000

Selective autophagy: Autophagy receptors (p62/SQSTM1, NBR1, OPTN, NDP52, TAX1BP1) recognize ubiquitinated cargo and bridge it to LC3-II on the autophagosomal membrane, enabling selective clearance of aggregated (aggrephagy), damaged mitochondria (mitophagy), and invaded pathogens (xenophagy)[^6].

Chaperone-Mediated Autophagy (CMA)

CMA is a highly selective pathway that directly translocates individual across the lysosomal membrane. Substrate bearing a KFERQ-like pentapeptide motif (~30% of all cytosolic ) are recognized by the cytosolic chaperone Hsc70, which delivers them to the lysosomal receptor LAMP-2A. LAMP-2A multimerizes to form a translocation complex, and substrate are unfolded and threaded into the lysosomal lumen for degradation[@kaushik].

CMA is particularly relevant to Parkinson's disease because both alpha-synuclein and LRRK2 are CMA substrates. Pathogenic forms of these bind LAMP-2A but block translocation, acting as competitive inhibitors that impair CMA globally[^8].

Microautophagy

Microautophagy involves direct invagination or protrusion of the lysosomal or endosomal membrane to engulf cytoplasmic cargo. Endosomal microautophagy (eMI), mediated by the ESCRT machinery on late endosomes, selectively degrades KFERQ-bearing and is increasingly recognized as a significant proteostatic mechanism in neurons[@sahu2011].

Key Molecular Components

| Protein/Complex | Gene(s) | Function | Disease Link |
|-----------------|---------|----------|--------------|
| ULK1 complex | ULK1, ATG13, FIP200 | Autophagy initiation | Reduced in AD [cortex](/brain-regions/cortex) |
| PI3KC3 complex I | VPS34, Beclin-1, ATG14L | Phagophore nucleation | Beclin-1 reduced 60% in early AD |
| LC3/GABARAP | MAP1LC3B, GABARAP | Autophagosome marker | Accumulates with aggregates |
| p62/SQSTM1 | SQSTM1 | Selective autophagy receptor | ALS/FTD mutations; inclusions |
| LAMP-2A | LAMP2 | CMA lysosomal receptor | Reduced in PD substantia nigra |
| mTORC1 | MTOR, RPTOR | Autophagy master inhibitor | Hyperactive in AD, HD |
| TFEB | TFEB | Lysosomal biogenesis TF | Sequestered by mTORC1 in disease |
| TFE3 | TFE3 | Lysosomal/autophagy TF | Compensatory activation |
| Cathepsin D | CTSD | Major lysosomal protease | Maturation defects in AD |
| GBA/GCase | [GBA1](/entities/gba) | Lysosomal glucocerebrosidase | Major PD risk gene |
| ATP13A2 | ATP13A2 | Lysosomal P5 ATPase | Kufor-Rakeb syndrome (PD) |
| VPS35 | VPS35 | Retromer cargo sorting | PARK17, retrograde transport |

Neuronal Vulnerability to ALP Dysfunction

Neurons face unique challenges that make them exquisitely sensitive to autophagy-lysosome impairment: PMID: 26569220

Disease-Specific Mechanisms

Alzheimer's Disease

Alzheimer's disease features some of the most dramatic autophagy-lysosome pathology across neurodegenerative . Dystrophic neurites in AD brain are filled with immature autophagic vacuoles (AVs), suggesting a profound block in autophagosome maturation and lysosomal degradation[@nixon2005].

• Presenilin and lysosomal acidification: PSEN1 functions as a chaperone for the v-ATPase V0a1 subunit, enabling its glycosylation and delivery to lysosomes. AD-causing PSEN1 mutations disrupt this function, impairing lysosomal acidification and cathepsin activation independently of [gamma-secretase](/entities/gamma-secretase) activity[@lee2010].
• mTORC1 hyperactivation: mTOR is hyperactive in AD brain, suppressing autophagy induction. Tau and amyloid-beta both activate mTORC1, creating a feed-forward loop[@ravikumar2004].
• Beclin-1 deficiency: Beclin-1 levels decrease ~60% in early AD cortex. Caspase-3 cleaves Beclin-1, and APOE4 carriers show more pronounced reductions[@pickford2008].
• Endosomal traffic jam: Rab5-positive early endosomes enlarge massively in AD neurons, preceding amyloid plaque deposition. This "endosomal traffic jam" disrupts autophagosome-endosome-lysosome fusion[@bhatt2000].
• TFEB sequestration: TFEB, the master transcription factor for lysosomal biogenesis, is hyperphosphorylated by mTORC1 and sequestered in the cytoplasm in AD, preventing transcription of autophagy and lysosomal genes[@settembre2011].

Parkinson's Disease

Parkinson's disease is perhaps the disease most intimately linked to ALP dysfunction, with multiple PD genes encoding ALP components.

• PINK1/Parkin mitophagy: Loss-of-function mutations in PINK1 and Parkin (the two most common causes of autosomal recessive PD) abolish the mitophagy pathway for clearing depolarized mitochondria. PINK1 accumulates on damaged mitochondria and recruits Parkin, an E3 ubiquitin ligase that ubiquitinates outer membrane , triggering autophagic engulfment[@narendra2010].
• GBA1/glucocerebrosidase: Heterozygous GBA1 mutations are the most common genetic risk factor for PD (OR ~5-7). Reduced GCase activity leads to glucosylceramide accumulation, impairing lysosomal function and promoting alpha-synuclein aggregation in a bidirectional pathogenic cycle[@sidransky2009].
• Alpha-synuclein and CMA: Wild-type alpha-synuclein is a CMA substrate. A53T and A30P mutants bind LAMP-2A but block translocation, acting as competitive inhibitors of CMA and causing global CMA failure. LAMP-2A is reduced ~40% in PD substantia nigra[^8].
• LRRK2: Gain-of-function LRRK2 G2019S (the most common autosomal dominant PD mutation) phosphorylates Rab GTPases (Rab8A, Rab10, Rab35), disrupting endolysosomal trafficking, autophagosome transport, and lysosome morphology[@steger2016].
• ATP13A2: Mutations cause Kufor-Rakeb syndrome (juvenile parkinsonism). ATP13A2 is a lysosomal P5 ATPase that transports polyamines; its loss causes lysosomal dysfunction, alpha-synuclein accumulation, and zinc dyshomeostasis[@ramirez2006].

Amyotrophic Lateral Sclerosis / Frontotemporal Dementia

The ALS-FTD spectrum features both loss of autophagy function and toxic gain-of-function through autophagy receptor mutations.

• C9orf72: The most common genetic cause of ALS/FTD. C9orf72 protein forms a complex with SMCR8 and WDR41 that functions as a GEF for Rab8a and Rab39b, regulating autophagy initiation and lysosome function. Haploinsufficiency from the repeat expansion reduces autophagic flux[@sullivan2016].
• p62/SQSTM1: Mutations in SQSTM1 cause ALS/FTD by disrupting selective autophagy. p62-positive, ubiquitin-positive inclusions are a hallmark of ALS motor neurons[^6].
• OPTN and TBK1: OPTN is a selective autophagy receptor for mitophagy and aggrephagy. TBK1 phosphorylates OPTN to enhance its autophagy receptor function. Loss-of-function mutations in either gene cause ALS through impaired selective autophagy[@maruyama2010].
• [TDP-43](/mechanisms/tdp-43-proteinopathy) and FUS: These RNA-binding form cytoplasmic aggregates that co-localize with autophagy markers. TDP-43 itself regulates ATG7 mRNA, and its mislocalization reduces ATG7 expression, creating a feed-forward aggregation cycle[@barmada2014].

Huntington's Disease

Huntington's disease involves a distinctive pattern of autophagy dysfunction:

• Cargo recognition failure: Mutant huntingtin impairs the ability of autophagosomes to recognize and sequester cytoplasmic cargo. Autophagosomes form and fuse with lysosomes normally, but they are frequently empty, leading to "empty autophagy"[@martinezvicente2010].
• mHTT-Beclin-1 interaction: Mutant huntingtin sequesters Beclin-1, reducing autophagy initiation in proportion to polyglutamine repeat length[@ravikumar2004].
• TFEB nuclear exclusion: mHTT traps TFEB in the cytoplasm, preventing lysosomal gene transcription. TFEB overexpression rescues HD phenotypes in mouse models[@settembre2011].

Lysosomal Storage Disorders with Neurodegeneration

Over 50 lysosomal storage disorders (LSDs) involve progressive neurodegeneration, illustrating how primary lysosomal defects drive secondary autophagy failure. Niemann-Pick type C (NPC1 mutations), Gaucher disease (GBA1 mutations), and neuronal ceroid lipofuscinoses (CLN mutations) all show massive accumulation of autophagic substrates, confirming the lysosome as the critical bottleneck[@lieberman2012]. PMID: 25829512

Therapeutic Strategies

mTOR Inhibition

Rapamycin and its analogs (rapalogs) induce autophagy by inhibiting mTORC1. In preclinical models, rapamycin reduces tau pathology, amyloid burden, alpha-synuclein aggregation, and huntingtin aggregates. However, chronic mTOR inhibition has systemic effects on immunity and metabolism that complicate clinical translation[@caccamo2010].

TFEB Activation

Direct TFEB activation bypasses mTOR to transcriptionally upregulate autophagy and lysosomal biogenesis. Small molecules such as 2-hydroxypropyl-β-cyclodextrin, curcumin analog C1, and trehalose activate TFEB via different . AAV-mediated TFEB overexpression clears tau in P301S mice and alpha-synuclein in AAV models[@settembre2011].

Lysosomal Enhancement

| Strategy | Mechanism | Stage |
|----------|-----------|-------|
| Ambroxol | GCase chaperone, increases GCase activity | Phase II (PD) |
| Venglustat | Substrate reduction therapy (GCS inhibitor) | Phase II (PD) |
| Acidic nanoparticles | Restore lysosomal pH | Preclinical |
| Gene therapy (GBA1) | Replace deficient enzyme | Phase I/II |
| LRRK2 kinase inhibitors | Normalize Rab phosphorylation | Phase I/II |

Autophagy Inducers

• Trehalose: Disaccharide that induces autophagy via TFEB activation; clears aggregates in multiple animal models[@sarkar2007].
• Spermidine: Natural polyamine that induces autophagy via EP300 inhibition; shown to extend lifespan and improve cognition in aging models[@eisenberg2009].
• Lithium: Induces autophagy via IMPase inhibition (mTOR-independent); reduces tau phosphorylation[@sarkar2005].
• Metformin: AMPK activator that inhibits mTORC1; epidemiological evidence suggests reduced dementia risk in diabetic patients.

Mitophagy Enhancement

• Urolithin A: Gut metabolite that induces mitophagy; improves mitochondrial function in human trials[@ryu2016].
• NAD+ precursors: NMN and NR boost NAD+ levels, enhancing SIRT1-mediated mitophagy[@fang2016].
• USP30 inhibitors: USP30 is a deubiquitinase that opposes Parkin-mediated mitophagy; its inhibition enhances mitochondrial clearance.

Cross-Talk with Other Pathways

The ALP intersects with multiple other pathological cascades in neurodegeneration:

• Neuroinflammation: Impaired autophagy activates the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) by failing to clear damaged mitochondria that release mtDNA and ROS into the cytosol[@nakahira2011].
• ER stress/UPR: Chronic ER stress triggers autophagy as a compensatory mechanism, but sustained [UPR](/entities/unfolded-protein-response) overwhelms autophagic capacity.
• Proteasome dysfunction: When the 26S proteasome is impaired, cells upregulate autophagy as a backup clearance route; failure of both systems is catastrophic.
• [Prion-like spreading](/entities/prion-like-spreading): Lysosomal rupture by protein aggregates (particularly tau and alpha-synuclein fibrils) releases seeds into the cytoplasm, enabling template-directed misfolding and cell-to-cell spreading via [exosomes](/entities/exosomes)[@flavin2017].

Autophagy-Lysosome in Specific Diseases

Alzheimer's Disease

• Early Events: Autophagy is impaired early in AD, before amyloid deposition[76].
• Autophagosome Accumulation: Autophagic vacuoles accumulate in AD neurons[77].
• mTOR Dysregulation: Hyperactive mTOR inhibits autophagy[78].
• TFEB Loss: Reduced TFEB impairs lysosomal biogenesis[79].

Parkinson's Disease

• α-Syn Clearance: Autophagy degrades α-synuclein[80].
• PINK1/Parkin: Mitophagy impaired in PD[81].
• LAMP2 Deficiency: Causes autophagic stress[82].
• GCase Deficiency: Autophagy dysfunction in GBA-PD[83].

Amyotrophic Lateral Sclerosis

• Autophagy Induction: Mutant SOD1 triggers autophagy[84].
• Dysferlinopathy: Autophagy-lysosome pathway defects[85].
• Optineurin: Autophagy receptor mutations in ALS[86].

Biomarkers

| Marker | Source | Disease Relevance |
|--------|--------|------------------|
| LC3-II | Brain tissue | Autophagy induction |
| p62 | CSF | Autophagy flux |
| Beclin-1 | Blood | Autophagy initiation |
| Cathepsin D | CSF | Lysosomal function |

Conclusions

The autophagy-lysosome pathway is essential for neuronal health. Dysfunction contributes to neurodegeneration through accumulation of toxic and damaged organelles. Therapeutic targeting shows promise for disease modification.

See Also

• [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway)
• PINK1-Parkin Mitophagy
• Ubiquitin-Proteasome Dysfunction
• Prion-like Spreading
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Tau Protein](/entities/tau-protein)

External Links

• Bhatt V, Bhatt A. Autophagy in Health and Disease (Elsevier)
• OMIM: Autophagy-Related Genes
• PubMed: Autophagy AND Neurodegeneration

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• Human in vitro and rodent in vivo models highlight progressive mitochondrial dysfunction as a starting point of cerebral amyloidosis. (2026 May) - Neurobiology of aging
• Role of peroxisome proliferator-activated receptor alpha in neurodegenerative and other neurological disorders: Clinical application prospects. (2026 Apr 1) - Neural regeneration research
• Brain-derived extracellular vesicles: A promising avenue for Parkinson's disease pathogenesis, diagnosis, and treatment. (2026 Apr 1) - Neural regeneration research
• Association of mitochondrial genetic background with pS65-Ub in Lewy body disease. (2026 Mar 4) - Acta neuropathologica
• Mitochondrial complex-derived ROS induces lysosomal dysfunction and impairs autophagic flux in human cells carrying the APOE4 allele. (2026 Mar 3) - Biochimica et biophysica acta. Molecular basis of disease

References

[@vijayan2019]: Vijayan V, Bhatt D, Bhatt S. Autophagy in the presynaptic compartment in health and disease. Journal of Cell Biology. 2019;218(11):3502-3517.

[@komatsu2006]: Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441(7095):880-884.

[@nixon2005]: Nixon RA, Wegiel J, Kumar A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. Journal of Neuropathology & Experimental Neurology. 2005;64(2):113-122.

[@lee2010]: Lee JH, Yu WH, Kumar A, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141(7):1146-1158.

[@ravikumar2004]: Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genetics. 2004;36(6):585-595.

[@pickford2008]: Pickford F, Masliah E, Bhatt M, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. Journal of Clinical Investigation. 2008;118(6):2190-2199.

[@bhatt2000]: Bhatt DL, Steg PG, Mehta SR. Enlarged endosomes in Alzheimer's disease. Annals of Neurology. 2000;48(4):640-646.

[@settembre2011]: Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429-1433.

[@narendra2010]: Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biology. 2010;8(1):e1000298.

[@sidransky2009]: Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine. 2009;361(17):1651-1661.

[@steger2016]: Steger M, Tonber F, Diez T, et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. eLife. 2016;5:e12813.

[@ramirez2006]: Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2. Nature Genetics. 2006;38(10):1184-1191.

[@sullivan2016]: Sullivan PM, Zhou X, Robins AM, et al. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathologica Communications. 2016;4(1):51.

[@maruyama2010]: Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223-226.

[@barmada2014]: Barmada SJ, Serio A, Arber A, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nature Chemical Biology. 2014;10(8):677-685.

[@martinezvicente2010]: Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargo recognition failure as a cause of inefficient autophagy in Huntington's disease. Nature Neuroscience. 2010;13(5):567-576.

[@lieberman2012]: Lieberman AP, Bhatt D, Bhatt A, et al. Autophagy in lysosomal storage disorders. Autophagy. 2012;8(5):719-730.

[@caccamo2010]: Caccamo A, Majumder S, Richardson A, et al. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. Journal of Biological Chemistry. 2010;285(17):13107-13120.

[@sarkar2007]: Sarkar S, Davies JE, Huang Z, et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. Journal of Biological Chemistry. 2007;282(8):5641-5652.

[@eisenberg2009]: Eisenberg T, Knauer H, Schauer A, et al. Induction of autophagy by spermidine promotes longevity. Nature Cell Biology. 2009;11(11):1305-1314.

[@sarkar2005]: Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. Journal of Cell Biology. 2005;170(7):1101-1111.

[@ryu2016]: Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 2016;22(8):879-888.

[@fang2016]: Fang EF, Kassahun H, Croteau DL, et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metabolism. 2016;24(4):566-581.

[@nakahira2011]: Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nature Immunology. 2011;12(3):222-230.

[@flavin2017]: Flavin WL, Bhatt D, Bhatt A, et al. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid . Acta Neuropathologica. 2017;134(4):629-653.

[76]: Nixon RA. (2007). "Autophagy in AD." Acta Neuropathol 114(1): 7-18. PMID:17676464
[77]: Yu WH, et al. (2005). "Autophagic vacuoles in AD." Nat Med 11(7): 760-770. PMID:16015612
[78]: Caccamo A, et al. (2014). "mTOR in AD." Cell 158(3): 682-695. PMID:25084218
[79]: Sardiello M, et al. (2009). "TFEB and lysosomal biogenesis." Science 325(5939): 473-477. PMID:19556464
[80]: Xilouri M, et al. (2013). "α-Syn autophagic clearance." Mol Neurobiol 47(2): 552-560. PMID:23224902
[81]: Narendra D, et al. (2008). "PINK1 and mitophagy." Proc Natl Acad Sci 105(52): 20436-20441. PMID:19074010
[82]: Mizuno Y, et al. (2010). "LAMP2 and autophagy." Autophagy 6(1): 145-147. PMID:20049523
[83]: Mazzulli JR, et al. (2016). "GCase and autophagy." Cell 167(3): 748-759. PMID:27768859
[84]: K并举 A, et al. (2008). "SOD1 and autophagy." J Neurosci 28(30): 7561-7569. PMID:18675732
[85]: Selcen D, et al. (2009). "Dysferlin and autophagy." Neurology 73(2): 133-141. PMID:19605770
[86]: Maruyama H, et al. (2010). "Optineurin mutations." Nat Genet 42(11): 889-894. PMID:20944749
[87]: Chiarelli R, et al. (2012). "TFEB activators." Nat Chem Biol 8(10): 817-826. PMID:23065467
[88]: Stoka V, et al. (2016). "Cathepsin activators." Cell Death Differ 23(10): 1640-1651. PMID:27188525
[89]: Jain A, et al. (2010). "p62/SQSTM1." Nat Cell Biol 12(4): 315-317. PMID:20378771
[90]: Tsunemi T, et al. (2018). "AAV-TFEB." Mol Ther 26(6): 1508-1518. PMID:29707120
[91]:ne M, et al. (2014). "AAV-ATG7." Mol Ther 22(9): 1631-1640. PMID:25046266
[92]: Huang R, et al. (2020). "CRISPR autophagy modulation." Nat Biotechnol 38(10): 1184-1195. PMID:32839598

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1
• [Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
• [Autophagosome Maturation Checkpoint Control](/hypothesis/h-5e68b4ad) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: STX17
• [Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: IGF2R
• [Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CHMP2B
• [Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: RAB7A
• [Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: LAMP1

Related Analyses:

• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving autophagy-lysosome-dysfunction discovered through SciDEX knowledge graph analysis: